Sign In
Buy ANIP
$80.58
+1.09 (+1.37%)
At Close: Jun 22, 2026
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:46am, Tuesday, 16'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
02:30pm, Wednesday, 10'th Jun 2026
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
02:26pm, Wednesday, 10'th Jun 2026
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
02:21pm, Wednesday, 10'th Jun 2026
ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company's defining investment narrative.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
10:46am, Friday, 29'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
06:50am, Wednesday, 27'th May 2026
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fire
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
12:51pm, Friday, 15'th May 2026
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
12:47pm, Friday, 15'th May 2026
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
12:40pm, Friday, 15'th May 2026
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Wednesday, 13'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
05:09pm, Monday, 11'th May 2026
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
12:31pm, Monday, 11'th May 2026
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
ANI Pharmaceuticals Q1 Earnings Call Highlights
04:07pm, Friday, 08'th May 2026
ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease compan
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
12:51pm, Friday, 08'th May 2026
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
10:31am, Friday, 08'th May 2026
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates an
